Drug Trial Radar · NCT07244263
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
91
Actual
Start
Jan 26, 2026
Primary completion
Feb 5, 2027
Study completion Feb 22, 2028
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Nov 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together. They start as small bumps but may become swollen and red over time. If they fill with pus, these lumps are called abscesses; these can also burst. Over time, the area can get scars and tunnels on or under the skin. Recent studies suggest that the condition may start when hair follicles become damaged and blocked. This impacts the skin and may activate the body's germ-fighting (immune) system. This allows bacteria to grow on the skin which worsens the condition and can cause abscesses. The main aims of this study are to learn how safe zasocitinib is, how well it works and how well adults with HS tolerate it compared with a placebo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 4 months (16 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. After the first 4 months, all participants (also those who initially received placebo) will then receive zasocitinib for up to 8 months (36 weeks). During the study, participants will visit their study clinic 12 times.
Conditions
- Hidradenitis Suppurativa
Interventions
Zasocitinib (Dose A)Drug
Zasocitinib.
PlaceboOther
Placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants who Achieve 75 Percent (%) Reduction in Hidradenitis Suppurativa Clinical Response (HiSCR75)Time frame: At Week 16
Locations
45 sites in 8 countries. Site status is shown where the registry gives one.
Mayo Clinic
Scottsdale, Arizona
Johnson Dermatology
Fort Smith, Arkansas
First OC Dermatology Research
Fountain Valley, California
Direct Helpers Research Center
Hialeah, Florida
Advanced Clinical Research Institute
Tampa, Florida
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Wayne State University
Detroit, Michigan
Hamzavi Dermatology
Fort Gratiot, Michigan
StracSkin, PLLC
Greenland, New Hampshire
Northwell Health Physician Partners
Lake Success, New York
Mount Sinai Doctors
New York, New York
Apex Clinical Research Center, LLC.
Mayfield Heights, Ohio
ODRC Enterprises, LLC dba Oregon Dermatology and Research Center
Portland, Oregon
Arlington Research Center, Inc.
Arlington, Texas
Texas Dermatology Research Center
Dallas, Texas
Skin & Cancer Foundation - The Skin Hospital
Darlinghurst, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Skin Health Institute Inc.
Carlton, Victoria, Australia
Sinclair Dermatology
Melbourne, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Beacon Dermatology
Calgary, Alberta, Canada
Brunswick Dermatology Center
Fredericton, New Brunswick, Canada
CCA Medical Research
Ajax, Ontario, Canada
SimcoDerm Medical and Surgical Dermatology Centre
Barrie, Ontario, Canada
SKiN Centre for Dermatology
Peterborough, Ontario, Canada
Innovaderm Research Inc.
Montreal, Quebec, Canada
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
Peking University First Hospital
Beijing, Beijing Municipality, China
Southern Medical Universtiy - Dermatology Hospital (SMUDH) (Guangdong Provincial Dermatology Hospital)
Guangzhou, Guangdong, China
Union Hospital Tongji Medical College of Huazhong University of Science and Technology (HUST)
Wuhan, Hubei, China
Huashan Hospital, Fudan University, Shanghai
Shanghai, Shanghai Municipality, China
CHU de Rouen
Rouen, France
CHU NICE
Nice, Alpes Maritimes, France
Hopital Edouard Herriot
Lyon, Rhone, France
Centre Hospitalier Le Mans
Le Mans, Sarthe, France
Charite Dermatology
Berlin, Germany
Fachklinik Bad Bentheim
Bad Bentheim, Lower Saxony, Germany
Katholisches Klinikum Bochum gGmB
Bochum, Northrhine Westfalia, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - Hautklinik und Poliklinik - Clinical Research Center (CRC)
Mainz, Rhineland-Palatine, Germany
ErasmusMC
Rotterdam, South Holland, Netherlands
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.